Drug · CHEMBL45
MELATONIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. MELATONIN. Drugs and targets, record CHEMBL45. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL45
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
- Circadin, General nutrit, Health aid, Heidadouppi, Icenia, Life ext, Melapure, Melatonin neurim, Natrol, Nature's blend, Natures bounty, Quality health, S.gard, Slenyto, Travelag, Vespro, Vytalonin
- ChEMBL
- Other names
- 5-methoxy n-acetyl-tryptamine, BCI-049, J5.258B, Melatol, Melatonine, Melovine, NSC-113928, NSC-302012, NSC-56423, Regulin, Tartrol
- ChEMBL
- Open Targets' highest stage
- Approval, for 2 of its 116 diseases, from EMA Human Drugs and TTD
- Open Targets
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| MTNR1A | Melatonin receptor | Melatonin receptor agonist | AGONIST | https://conductscience.org/library/genes/4543 |
| MTNR1B | Melatonin receptor | Melatonin receptor agonist | AGONIST | https://conductscience.org/library/genes/4544 |
Source ChEMBL
Diseases116
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 116Source Open Targets
See all 116 diseasesTrials368
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00397189 | Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients | Phase 3 | 930 | 2011-03-28 | melatonin | Its name | ClinicalTrials.gov |
| NCT01700959 | Melatonin Intervention For Neurocognitive Deficits in the St. Jude Lifetime Cohort | Phase 3 | 911 | 2018-06-28 | melatonin | Its name | ClinicalTrials.gov |
| NCT04795336 | Melatonin Use After Primary Total Joint Arthroplasty | Phase 1 | 294 | 2025-05-04 | melatonin | Its name | ClinicalTrials.gov |
| NCT02654314 | Prevention of Delirium in Inpatients Utilizing Melatonin | Phase 3 | 277 | 2019-02-12 | melatonin | Its name | ClinicalTrials.gov |
| NCT05439876 | Getting SMART for Pediatric Epilepsy | Phase 2/3 | 147 | 2025-08-29 | melatonin | Its name | ClinicalTrials.gov |
| NCT02251041 | Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL) | Phase 2 | 143 | 2024-08-23 | melatonin | Its name | ClinicalTrials.gov |
| NCT00705003 | Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD) | Phase 2 | 142 | 2014-06-18 | melatonin | Its name | ClinicalTrials.gov |
| NCT01906866 | Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities | Phase 3 | 125 | 2018-10-30 | melatonin | Its name | ClinicalTrials.gov |
| NCT02691702 | Multiple Dose Study Of BIIB118 (PF-05251749) In Healthy Volunteers | Phase 1 | 97 | 2018-10-15 | melatonin | Its name | ClinicalTrials.gov |
| NCT01805089 | Melatonin Versus Placebo in Breast Cancer | Early phase 1 | 95 | 2015-02-23 | melatonin | Its name | ClinicalTrials.gov |
1 to 10 of 368
See all 368 trialsComparisons in its trials60
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Circadin vs Placebo: serious adverse events | 1 of 394 | 3 of 395 | 789 | NCT00397189 | Trial comparisons |
| Melatonin vs Cellulose Microcrystylline: Delirium | 2 of 136 | 8 of 141 | 277 | NCT02654314 | Trial comparisons |
| Melatonin vs Cellulose Microcrystylline: deaths from any cause | 0 of 136 | 0 of 141 | 277 | NCT02654314 | Trial comparisons |
| Melatonin vs Cellulose Microcrystylline: serious adverse events | 0 of 136 | 0 of 141 | 277 | NCT02654314 | Trial comparisons |
| Melatonin vs Placebo: deaths from any cause | 0 of 137 | 0 of 138 | 275 | NCT05439876 | Trial comparisons |
| Melatonin vs Placebo: serious adverse events | 0 of 137 | 0 of 138 | 275 | NCT05439876 | Trial comparisons |
| Circadin 2/5/10 mg vs Placebo: Number of Dropouts | 9 of 60 | 21 of 65 | 125 | NCT01906866 | Trial comparisons |
| Melatonin vs Placebo: Compliance | 43 of 48 | 43 of 47 | 95 | NCT01805089 | Trial comparisons |
| Melatonin vs Placebo: serious adverse events | 0 of 48 | 0 of 47 | 95 | NCT01805089 | Trial comparisons |
| Melatonin1+3 vs Placebo: serious adverse events | 5 of 40 | 7 of 41 | 81 | NCT01690000 | Trial comparisons |
1 to 10 of 60
See all 60 comparisons in its trialsPapers from its trials191
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials13
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Psychomotor Vigilance Task | 2 | 0 | ConductCognition |
| Stroop Color-Word Test | 2 | 0 | ConductCognition |
| Trail Making Test A | 2 | 1 | ConductCognition |
| Trail Making Test B | 2 | 1 | ConductCognition |
| Corsi Block-Tapping Test | 1 | 0 | ConductCognition |
| Finger Tapping Task | 1 | 0 | ConductCognition |
| Paced Visual Serial Addition Test | 1 | 1 | ConductCognition |
| Picture Naming Test | 1 | 0 | ConductCognition |
| Simple Reaction Time | 1 | 0 | ConductCognition |
| Symbol Coding | 1 | 0 | ConductCognition |
1 to 10 of 13
See all 13 tests in its trialsData dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL45
GET https://conductscience.org/api/drugs/v1/CHEMBL45/diseases?page=2